Cannabis laws have changed rapidly across the United States. As medical and adult-use markets expand, researchers are examining how legal access may affect healthcare decisions—including the use of prescription anxiety medications.

A 2024 study found that cannabis legalization was associated with lower benzodiazepine prescription fill rates. However, the findings do not prove that patients replaced their medications with cannabis. They also do not establish cannabis as a safe or effective treatment for anxiety.

Understanding that distinction is essential for patients, healthcare providers, and businesses following the evolving cannabis market.

Anxiety Disorders Are a Major Health Concern

Anxiety disorders affect approximately 301 million people worldwide, according to the World Health Organization.

These disorders involve more than occasional stress or worry. Symptoms may interfere with work, school, relationships, and everyday activities. Common conditions include:

• Generalized anxiety disorder
• Panic disorder
• Social anxiety disorder
• Phobia-related disorders

Symptoms vary from person to person. They may include persistent worry, difficulty concentrating, restlessness, sleep problems, rapid heartbeat, and sweating.

The National Institute of Mental Health notes that anxiety disorders can significantly affect daily life. However, evidence-based treatments can help many people manage their symptoms.

How Anxiety Disorders Are Commonly Treated

Treatment depends on the type and severity of the condition, the patient’s health, and other individual factors. A healthcare provider may recommend psychotherapy, medication, or a combination of treatments.

Psychotherapy

Cognitive behavioral therapy, commonly known as CBT, is frequently used to treat anxiety. It helps patients recognize unhelpful thought patterns and develop healthier ways to respond to stressful situations.

Antidepressants

Selective serotonin reuptake inhibitors and similar medications are often used as first-line treatments. These medications may take several weeks to produce their full effects.

Benzodiazepines

Benzodiazepines, including lorazepam and diazepam, can provide short-term relief from certain anxiety symptoms. However, they may cause dependence and withdrawal problems, particularly when used for an extended period.

Patients should never stop or change a prescribed anxiety medication without consulting a qualified healthcare professional.

Why Cannabis Has Entered the Conversation

Growing access to legal cannabis has encouraged interest in its possible mental health applications. Some patients report using cannabis products to manage stress, improve sleep, or cope with anxiety symptoms.

Cannabis contains many chemical compounds, including tetrahydrocannabinol and cannabidiol.

THC and CBD Are Different

THC is primarily responsible for cannabis’s intoxicating effects. Its effects can vary based on the dose, product, method of consumption, and individual user.

CBD does not produce the same intoxicating effect. It has attracted considerable interest for its possible therapeutic properties, including potential effects on anxiety.

However, public interest does not establish medical effectiveness. Cannabis products can produce different responses, and THC may increase anxiety or discomfort for some people.

What the Prescription Research Found

A study published in JAMA Network Open examined prescription data from commercially insured patients between 2007 and 2020. Researchers evaluated whether state medical and recreational cannabis laws were associated with changes in prescriptions for several mental health medications.

The study reported that:

• Medical cannabis laws were associated with a 12.4% reduction in benzodiazepine prescription fill rates.
• Recreational cannabis laws were associated with a 15.2% reduction in benzodiazepine prescription fill rates.
• Medical cannabis laws were associated with a small reduction in the average number of benzodiazepine prescriptions filled per patient.
• Prescription patterns differed across medication types and cannabis policies.

The researchers also observed increases in the use of certain antidepressants and antipsychotic medications following some cannabis policy changes. Therefore, the results do not show a consistent decline across all mental health prescriptions.

What the Study Does Not Prove

The findings are noteworthy, but they require careful interpretation.

The study identified changes in prescription patterns after cannabis policies took effect. It did not track whether individual patients stopped taking benzodiazepines because they started using cannabis.

It also did not establish that cannabis:

• Treats anxiety effectively
• Is safer than prescription medication
• Produces better patient outcomes
• Can replace psychotherapy or clinician-directed treatment
• Is appropriate for every person with an anxiety disorder

Other factors could have contributed to the prescription changes. These may include updated prescribing practices, growing awareness of benzodiazepine risks, changes in insurance coverage, and broader shifts in mental healthcare.

Additional clinical research is needed to determine whether cannabis directly influences medication use and patient outcomes.

Why Patient Preferences May Be Changing

Although the study did not examine individual motivations, several factors may influence interest in cannabis.

Concerns About Prescription Medication

Some patients worry about side effects, dependence, or withdrawal associated with certain medications. These concerns may encourage them to explore other options.

Perceptions of Cannabis

Cannabis is sometimes perceived as natural and therefore safer. However, natural products can still cause side effects, interact with medications, or create health risks.

Increased Availability

Legalization makes cannabis products easier to access. Dispensaries also offer a growing selection of products, doses, and consumption methods.

Personal Experiences

Recommendations from friends, relatives, and online communities can influence treatment decisions. However, personal experiences are not a substitute for controlled clinical research or professional medical guidance.

Is CBD Approved for Treating Anxiety?

The U.S. Food and Drug Administration has approved only one prescription drug containing purified CBD. That medication is used to treat specific seizure disorders—not anxiety.

The FDA warns that nonprescription CBD products may carry risks, including:

• Liver injury
• Interactions with other medications
• Drowsiness or changes in alertness
• Gastrointestinal problems
• Mood changes
• Inaccurate labeling
• Exposure to contaminants

Many consumer CBD products have not been evaluated for effectiveness, appropriate dosing, or long-term safety. Patients should discuss CBD and cannabis use with a healthcare provider, especially when taking prescription medication.

Implications for Healthcare Providers

As cannabis becomes more accessible, healthcare providers may encounter more patients who use it for anxiety or other mental health concerns.

Open communication is important. Patients may be reluctant to disclose cannabis use if they expect judgment or dismissal. Providers can encourage honest conversations by discussing potential benefits, uncertainties, medication interactions, and risks.

Patient-centered care does not mean accepting every alternative treatment as effective. It means considering the patient’s experiences while using reliable evidence to guide decisions.

Implications for Pharmaceutical Research

Changing prescription patterns may encourage additional research into cannabinoids and mental health treatment.

Future studies could help determine:

• Which cannabinoids may affect anxiety symptoms
• How THC-to-CBD ratios influence outcomes
• Which doses may be effective or harmful
• How cannabis interacts with common medications
• Which patients face an increased risk of adverse effects
• Whether any benefits continue with long-term use

Standardized clinical products and controlled trials will be necessary before researchers can draw firm conclusions.

Cannabis Risks and Safety Considerations

Cannabis products are not interchangeable. Potency, ingredients, manufacturing standards, and labeling requirements can vary between products and states.

Patients should consider several risks before using cannabis for anxiety.

Individual Responses Vary

A product that one person finds calming may cause anxiety, panic, impaired judgment, or discomfort in someone else.

Product Quality Can Differ

Products may contain more or less THC or CBD than their labels indicate. Contaminants, including pesticides and heavy metals, may also be a concern when products are not properly regulated or tested.

Drug Interactions Are Possible

Cannabis and CBD may affect how the body processes certain medications. Combining products without medical guidance could increase side effects or reduce treatment effectiveness.

Over-Reliance Can Create Problems

Using cannabis as the only response to anxiety may prevent someone from addressing underlying symptoms or obtaining appropriate care. Anyone experiencing severe, persistent, or worsening anxiety should seek professional support.

The Future of Cannabis and Anxiety Research

Cannabis legalization has created an opportunity to study how access affects patient behavior, prescription use, and health outcomes.

The decline in benzodiazepine prescription fills identified in the JAMA study is an important finding. Still, it represents one piece of a much larger clinical and public-health question.

Future research must move beyond prescription data. Researchers will need to examine patient symptoms, cannabis consumption, dosage, side effects, medication changes, and long-term outcomes.

Conclusion

Cannabis legalization is associated with changes in anxiety medication prescriptions, particularly benzodiazepines. However, current evidence does not prove that cannabis caused the decline or that patients can safely replace prescribed treatment with cannabis.

Cannabis and CBD may eventually play a role in certain mental health treatments. For now, important questions remain about effectiveness, dosing, product quality, drug interactions, and long-term safety.

Patients should make treatment decisions with qualified healthcare professionals. Meanwhile, researchers, regulators, and cannabis businesses must communicate responsibly and avoid presenting emerging evidence as settled medical fact.

This article is for general informational purposes only and is not medical advice. Do not start, stop, or change a prescribed medication without consulting a qualified healthcare professional.